SOURCE: Avadim Technologies Inc.

Avadim Technologies Inc.

June 07, 2016 09:00 ET

Avadim Technologies Introduces Its Theraworx® Sports Medicine Technology at the 67th National Athletic Trainers Association Clinical Symposia & AT Expo, in Baltimore, MD June 22-25, 2016

Avadim to Introduce Trusted Clinical Low pH Topical Protective Technology Into Sports Medicine Market

ASHEVILLE, NC--(Marketwired - June 07, 2016) - Avadim Technologies, Inc. ("Avadim"), a life sciences company delivering Pathogenesis Based Therapies ("PBTs"), which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue, announced today that Theraworx® Technology, its proven low pH topical therapy for prevention of adverse clinical conditions, will be showcased at the 67th National Athletic Trainers Association ("NATA") Clinical Symposia & AT Expo, in Baltimore, MD on June 22-25, 2016.

According to NATA, this year's Clinical Symposia will bring more athletic trainers under one roof than any other tradeshow. It is the world's premier exhibition in sports medicine, with over 350 exhibitors and thousands of athletic trainers converging for a 3-day marketplace of products, education and services to outfit training facilities.

Stephen Woody, Chairman and CEO, stated, "We are pleased to launch Theraworx®, our proven Hospital-Acquired Condition (HAC) solution, to the sports medicine market. Many of the same skin integrity and infection risks confronting healthcare facilities, challenge the health and well-being of our athletes nationwide."

Mr. Woody continued, "We are extremely gratified by the recent outcomes achieved by a major Southeast Division I University wrestling team which demonstrated significant reduction in the incidence of topical skin conditions even in the difficult 'active transmission' environment that occurs wrestler-to-wrestler and mat-to-wrestler. This University did not have any down mat time the entire season, which was a first in the history of the program. We are bringing the same principles used in over 200 hospital ICU's across the country to the locker room and have now have demonstrated consistent results."

Scientific evidence suggests maintaining and lowering the pH of the body's largest organ, the skin, optimizes the natural antimicrobial acidic mantle of the stratum corneum, the outer layer of the skin. This same low pH approach has also been shown to improve skin cohesion and integrity, and prevent trans-epidermal water loss. While originally formulated for clinical healthcare applications, the patented low pH formulation of Theraworx® offers an exciting new tool to sports medicine practitioners.

The NATA Clinical Symposia & AT Expo will be held at Baltimore Convention Center in Baltimore, MD on June 22-25, 2016. Athletic trainers are encouraged to visit Theraworx® at booth number 6143.

About Theraworx®:
Avadim's patented Theraworx® products and patent-pending protocols have demonstrated a proven ability to help hospitals control hospital-acquired conditions. The unique Theraworx® formula helps preserve the body's natural skin function, by preventing dry skin and helping to maintain the natural acidic, anti-microbial nature of the skin's outermost layer. For more information on Theraworx®, visit www.theraworx.com.

About Avadim Technologies, Inc.:
Avadim Technologies, Inc. is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies ("PBTs") which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim's advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.

For more information on Avadim, visit www.avadimtechnologies.com.

Contact Information